» Articles » PMID: 31191822

Comparative Genomic Analysis of Driver Mutations in Matched Primary and Recurrent Meningiomas

Overview
Journal Oncotarget
Specialty Oncology
Date 2019 Jun 14
PMID 31191822
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

A significant proportion of low-grade WHO grade I and higher-grade WHO grade II or III meningiomas are at risk to develop post-resection recurrence. Though recent studies investigated genomic alterations within histological subtypes of meningiomas, few have compared genomic profiles of primary meningiomas matched to their recurrences. The present study aimed to identify oncogenic driver mutations that may indicate risk of meningioma recurrence and aggressive clinical course. Seventeen patients treated for low-grade ( = 8) or high-grade ( = 9) meningioma and underwent both primary and recurrent resection between 2007-2017 were reviewed. Tumor specimens ( = 38) underwent genomic sequencing of known oncogenic driver mutations. Primary and recurrent tumors were compared using matched-pair analyses for mutational associations with clinical outcomes including functional status, progression-free survival (PFS) and overall survival (OS). Most common driver mutations included and . There was no enrichment for any driver mutation from primary to recurrent tumor specimen. mutant meningiomas were associated with larger tumor size (8-fold increase), presence of vasogenic edema, and higher mitotic proliferation on univariate and independently on multivariate regression (p's < 0.05) after controlling for preoperative and tumor features. Tumors with driver mutations were associated with decreased functional status at last postoperative follow-up ( = 0.022) relative to presentation. Mutation status was not associated with PFS or OS on multivariate Cox regression, but rather with grade of resection ( = 0.046) for PFS. While primary and recurrent tumors exhibited similar driver mutations within patients, the identification of driver mutations associated with clinical outcomes is crucial for guiding potential targeted treatments in recurrent meningiomas.

Citing Articles

Molecular biomarkers in meningioma (Review).

Dwianingsih E, Krisnugraha Y, Bawono R, Malueka R Biomed Rep. 2025; 22(4):56.

PMID: 39991008 PMC: 11843207. DOI: 10.3892/br.2025.1934.


Role of Mutation in the Development of Eleven Different Cancers.

Hosseingholi Nouri S, Nitturi V, Ledbetter E, English C, Lau S, Klisch T Cancers (Basel). 2025; 17(1.

PMID: 39796693 PMC: 11720051. DOI: 10.3390/cancers17010064.


A four-hit mechanism is sufficient for meningioma development.

Devarajan A, Seah C, Zhang J, Vasan V, Feng R, Chapman E J Neurooncol. 2024; 171(3):599-607.

PMID: 39586894 DOI: 10.1007/s11060-024-04877-y.


The Impact of Molecular and Genetic Analysis on the Treatment of Patients with Atypical Meningiomas.

Ravnik J, Rowbottom H Diagnostics (Basel). 2024; 14(16).

PMID: 39202270 PMC: 11353905. DOI: 10.3390/diagnostics14161782.


Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma.

Joshi R, Sharma A, Kulshreshtha R Mol Ther Oncol. 2024; 32(1):200782.

PMID: 38596289 PMC: 10951709. DOI: 10.1016/j.omton.2024.200782.


References
1.
Loewenstern J, Aggarwal A, Pain M, Barthelemy E, Costa A, Bederson J . Peritumoral Edema Relative to Meningioma Size Predicts Functional Outcomes after Resection in Older Patients. Oper Neurosurg (Hagerstown). 2018; 16(3):281-291. DOI: 10.1093/ons/opy107. View

2.
Jenkinson M, Javadpour M, Haylock B, Young B, Gillard H, Vinten J . The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. Trials. 2015; 16:519. PMC: 4650615. DOI: 10.1186/s13063-015-1040-3. View

3.
Petrilli A, Fernandez-Valle C . Role of Merlin/NF2 inactivation in tumor biology. Oncogene. 2015; 35(5):537-48. PMC: 4615258. DOI: 10.1038/onc.2015.125. View

4.
Pain M, Wang H, Lee E, Strahl M, Hamou W, Sebra R . Treatment-associated DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma. Oncotarget. 2018; 9(2):2603-2621. PMC: 5788663. DOI: 10.18632/oncotarget.23517. View

5.
Harmanci A, Youngblood M, Clark V, Coskun S, Henegariu O, Duran D . Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun. 2017; 8:14433. PMC: 5316884. DOI: 10.1038/ncomms14433. View